Home Metabolism Factor Xa

Factor Xa

Factor Xa is involved in blood coagulation cascade. Factor Xa is a protease which can convert prothrombin into thrombin by catalyzing the cleavage of prothrombin. Factor Xa inhibitors can be antithrombotic drug because thrombin is a key enzyme in thrombosis and hemostasis and the generation of thrombin depend on factor Xa.

Other Metabolism Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) PDE DHFR Carbonic Anhydrase
Cat.No. Product Name Information Product Use Citations Product Validations
S1346 Heparin Sodium Heparin sodium, a sulfated polysaccharide belonging to the family of glycosaminoglycans, has numerous important biological activities associated with its interaction with diverse proteins. Heparin is used as an anticoagulant primarily through its interaction with AT III by enhancing AT-IIImediated inhibition of blood coagulation factors, including thrombin and factor Xa. Heparin prevents the induction of autophagy.
Cell Rep Med, 2025, 6(10):102410
Bone Res, 2025, 13(1):37
Theranostics, 2025, 15(6):2597-2623
S1593 Apixaban Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
Neuropharmacology, 2025, 278:110569
TH Open, 2025, 9:a25475710
Nat Commun, 2024, 15(1):3912
Verified customer review of Apixaban
S3002 Rivaroxaban Rivaroxaban is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM in cell-free assays, respectively. It is selective for human factor Xa, for which this compound has >10 000-fold greater selectivity than for other biologically relevant serine proteases (IC50 >20 μM).
Thromb Haemost, 2025, 10.1055/a-2497-4213
TH Open, 2025, 9:a25475710
Cancer Cell, 2024, 42(10):1676-1692.e11
Verified customer review of Rivaroxaban
S7280 Edoxaban tosylate Monohydrate Edoxaban (DU-176b) is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.
J Immunother Cancer, 2024, 12(11)e009805
J Thromb Haemost, 2020, 18(8):1866-1873
Viruses, 2020, 10;12(6):E629
S4429 Edoxaban Edoxaban (DU-176b, Savaysa), an antithrombotic agent, is a selective, potent and orally active inhibitor of factor Xa (FXa) with Ki of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
Int J Lab Hematol, 2024, 10.1111/ijlh.14300
Cancer Lett, 2023, 553:215983
Thromb Res, 2023, 227:17-24
S5388 Betrixaban Betrixaban is a new, long-acting, oral and selective Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S5389 Betrixaban maleate Betrixaban maleate is the maleate salt form of Betrixaban, which is a Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S3736 Fondaparinux Sodium (Org 31540) Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.
E1789New Asundexian Asundexian (BAY 2433334) is an orally administered inhibitor of coagulation Factor XIa (FXIa). It binds reversibly to the FXIa active site with high affinity, blocking its enzymatic function. In buffer systems, Asundexian exhibits an IC50 of 1 nM against human FXIa.
E5835 Heparin Heparin is a highly sulfated polysaccharide primarily used as an anticoagulant, which works mainly by inhibiting thrombin (FIIa) and/or factor Xa (FXa). It is commonly used to prevent and treat thromboembolic conditions such as deep vein thrombosis and pulmonary embolism. It also plays roles in inflammation, angiogenesis, and growth factor signalling, with potential therapeutic applications in cancer treatment and allergic conditions.